Skip Navigation

European Heart Journal 1987 8(6):618-623;
Copyright © 1987 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by ALIOT, E.
Right arrow Articles by GILGENKRANTZ, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ALIOT, E.
Right arrow Articles by GILGENKRANTZ, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1987 The European Society of Cardiology

Electrophysiologic effects and pharmacokinetics of intravenous penticainide (CM 7857)

E. ALIOT*,, A. MUNOZ{dagger}, K. KHALIFE*, J. NECCIARI{dagger}, J. P. GAGNOL{dagger} and J. M. GILGENKRANTZ*

*Service cardiologie, C.H.U. Nancy 29 avenue Marechal Delattre de Tassigny, 54000 Nancy, France
{dagger}Sanofi Recherches, rue du Professeur Joseph Blayac 34082 Monipellier Cedex, France

Received 2 June 1986; revised 30 September 1986; .

Prof. E. Aliot, C.H.U. Nancy, Service cardiologie, 29 avenue Maréchal Delattre de Tassigny, 54000 Nancy, France

Abstract

Penticainide is a new class I antiarrhythmic agent. Its electrophysiological effects and pharmacokinetic properties were studied in 28 patients undergoing endocavitary exploration for paroxysmal supraventricular tachycardia (10 cases), WPW syndrome involving an accessory pathway (5 cases), and unexplained dizziness (13 cases). Increasing doses of penticainide were infused in the first 18 patients (0.12 up to 3.5 mg kg–1). The next ten patients received 4 mg kg–1 over a 30 minute period. Penticainide shortened the sinus cycle length and increased the transnodal conduction time. The ventricular conduction time tended to increase. Atrial functional refractory period increased when atrioventricular nodal and ventricular refractory periods remained unchanged. In patients with previous supraventricular tachycardials all triggered arrhythmias were prevented with dosages higher than 2 mg kg–1 and related blood levels higher than 3 mg l–1. A dose-dependency of plasma and renal clearance was documented. Average Cmax values after 4 mg kg–1 was 7.37 ± 1.28 mg l–1. No adverse events occurred during the trial and penticainide proved to be well tolerated.

Key Words: Pharmacokinetics • antiarrhythmic drugs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.